CEO: Sujal Shah

Sector: Healthcare
Industry:Biotechnology

Exchange: Nasdaq Global Select

Country: USA

Description: CymaBay Therapeutics Inc is an American biotechnology enterprise. Its product candidates include Arhalofenate, MBX-8025, and MBX-2982, which are meant to combat serious metabolic diseases.


Key numbers

Market Capitalization:138776020
Shares Outstanding: 68701000
Float: 61109608
Next Earning Date:2020-03-18
TTm EPS: -1.4325
TTm Dividend Rate:
200 days moving average:6.62
50 days moving average: 2.78
One day percent Change: 3.06



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,